ClinicalTrials.gg
CompletedNCT03326856Updated Apr 21, 2022Results posted

ET-01 in Subjects With Lateral Canthal Lines

A Phase 2 interventional study of botulinum toxin, Type A and Vehicle in Lateral Canthal Lines and Crow's Feet, sponsored by Eirion Therapeutics Inc.. Completed at 1 site in United States. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-04-21.

Sponsored by Eirion Therapeutics Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Study summary

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

Read the detailed description

This product is being tested for its ability to reduce lateral canthal lines, also known as Crow's Feet.

02

Conditions studied

  • Lateral Canthal Lines
  • Crow's Feet
03

In context

Lead sponsor

Eirion Therapeutics Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 25 - 65 years of age
  • minimal to moderate Crow's Feet wrinkles at rest
  • moderate to severe Crow's Feet wrinkles on contraction
  • willingness to refrain from any product affecting skin remodeling
  • female subjects must be not pregnant and non-lactating-

Exclusion criteria

Exclusion Criteria:

  • history of adverse reactions to any prior botulinum toxin treatments
  • history of vaccination or non-response to any prior botulinum toxin treatments
  • botulinum toxin treatment in the prior 6 months
  • present or history of neuromuscular disease, eyelid ptosis, muscle weakness, paralysis, or "dry eye"
  • history of peri-ocular surgery, brow lift or related procedures
  • procedures affecting the lateral canthal region in the prior 12 months
  • application of topical prescription medication to the treatment area
  • female subjects who are pregnant or are nursing a child
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Placebo comparator
    Vehicle

    Vehicle

    Biological: Vehicle

  • Experimental
    Dose 1

    botulinum toxin, Type A, Dose 1

    Biological: botulinum toxin, Type A

  • Experimental
    Dose 2

    botulinum toxin, Type A, Dose 2

    Biological: botulinum toxin, Type A

  • Experimental
    Dose 3

    botulinum toxin, Type A, Dose 3

    Biological: botulinum toxin, Type A

  • Experimental
    Dose 4

    botulinum toxin, Type A, Dose 4

    Biological: botulinum toxin, Type A

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Response Defined as IGA-C (Investigators Global Assessment) Score ≤ 2 and a SSA-C (Subject Self-Assessment) Score ≤ 2

    Composite of Investigators Global Assessment \& Subject Self-Assessment on contraction. Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe). The same scale is used for the Investigator's Assessment as well as the Subject's Self Assessment. To count, both assessments (on contraction) have to be "responders" defined as Score ≤ 2.

    Time frame: Week 4

Secondary outcomes

  1. Total Number of Observations With a Response Defined as IGA-C Score ≤ 2

    Total number of observations with a Score of ≤ 2 on the Investigators Global Assessment on Contraction, IGA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as Score ≤ 2. The observation period ranges from the earliest expected onset of action at Week 2 to the likely offset of action by Week 18.

    Time frame: Week 2, 4, 8,12,18

  2. Total Number of Observations With a Response Defined as SSA-C Score ≤ 2

    Total number of observations with a Score of ≤ 2 on the Subject Self-Assessment on Contraction, SSA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as Score ≤ 2. The observation period ranges from the earliest expected onset of action at Week 2 to the likely offset of action by Week 18.

    Time frame: Week 2, 4, 8,12,18

07

Results

Posted Sep 10, 2021

Participant flow

Participant flow — Overall Study
MilestoneVehicleDose 1Dose 2Dose 3Dose 4
Started139998
Completed128998
Not completed11000
Withdrew: Lost to follow-up11000

Outcome measures

PrimaryNumber of Participants With a Response Defined as IGA-C (Investigators Global Assessment) Score ≤ 2 and a SSA-C (Subject Self-Assessment) Score ≤ 2

Composite of Investigators Global Assessment \& Subject Self-Assessment on contraction. Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe). The same scale is used for the Investigator's Assessment as well as the Subject's Self Assessment. To count, both assessments (on contraction) have to be "responders" defined as Score ≤ 2.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Number of Participants With a Response Defined as IGA-C (Investigators Global Assessment) Score ≤ 2 and a SSA-C (Subject Self-Assessment) Score ≤ 2
ParticipantsVehicleDose 1Dose 2Dose 3Dose 4
Number of Participants With a Response Defined as IGA-C (Investigators Global Assessment) Score ≤ 2 and a SSA-C (Subject Self-Assessment) Score ≤ 223421
SecondaryTotal Number of Observations With a Response Defined as IGA-C Score ≤ 2

Total number of observations with a Score of ≤ 2 on the Investigators Global Assessment on Contraction, IGA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as Score ≤ 2. The observation period ranges from the earliest expected onset of action at Week 2 to the likely offset of action by Week 18.

Time frame:
Week 2, 4, 8,12,18
Reported as:
Count of units · Observations
Total Number of Observations With a Response Defined as IGA-C Score ≤ 2
ObservationsVehicleDose 1Dose 2Dose 3Dose 4
Total Number of Observations With a Response Defined as IGA-C Score ≤ 2161722169
SecondaryTotal Number of Observations With a Response Defined as SSA-C Score ≤ 2

Total number of observations with a Score of ≤ 2 on the Subject Self-Assessment on Contraction, SSA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as Score ≤ 2. The observation period ranges from the earliest expected onset of action at Week 2 to the likely offset of action by Week 18.

Time frame:
Week 2, 4, 8,12,18
Reported as:
Count of units · Observations
Total Number of Observations With a Response Defined as SSA-C Score ≤ 2
ObservationsVehicleDose 1Dose 2Dose 3Dose 4
Total Number of Observations With a Response Defined as SSA-C Score ≤ 2201926158

Adverse events

Collected over 26 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle0/13 (0%)0/13 (0%)0/13 (0%)
Dose 10/9 (0%)0/9 (0%)0/9 (0%)
Dose 20/9 (0%)0/9 (0%)1/9 (11.1%)
Dose 30/9 (0%)0/9 (0%)0/9 (0%)
Dose 40/8 (0%)0/8 (0%)1/8 (12.5%)
Most frequent other events
Most frequent other events
EventVehicleDose 1Dose 2Dose 3Dose 4
Myocardial infarctionCardiac disorders0/130/90/90/91/8
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/130/91/90/90/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)VehicleDose 1Dose 2Dose 3Dose 4Total
<=18 years000000
Between 18 and 65 years13999848
>=65 years000000
Sex: Female, Male
Sex: Female, Male(Participants)VehicleDose 1Dose 2Dose 3Dose 4Total
Female11897843
Male210205
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VehicleDose 1Dose 2Dose 3Dose 4Total
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White13898846
More than one race000000
Unknown or Not Reported010102
Region of Enrollment
Region of Enrollment(participants)VehicleDose 1Dose 2Dose 3Dose 4Total
United States13999848
IGA-C
IGA-C(units on a scale)VehicleDose 1Dose 2Dose 3Dose 4Total
Mean3.5 ± 0.43.6 ± 0.53.4 ± 0.53.4 ± 0.53.5 ± 0.53.5 ± 0.5
SSA-C
SSA-C(units on a scale)VehicleDose 1Dose 2Dose 3Dose 4Total
Mean3.5 ± 0.53.6 ± 0.53.4 ± 0.53.5 ± 0.53.4 ± 0.53.5 ± 0.5
08

Study locations

1 site
  • Cary Skin Care
    Cary, North Carolina 27519, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Jun 2018, 7 months.

Results were first posted in Sep 2021, 3 years 2 months after primary completion. A results delay was requested in Jul 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2017
First posted
Oct 31, 2017
StartActual
Oct 25, 2017
Primary completionActual
Jun 11, 2018
CompletionActual
Nov 14, 2018
Results delay requested
Jul 1, 2019
Results first posted
Sep 10, 2021
Last update
Apr 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03326856
Lead sponsor
Eirion Therapeutics Inc.
Responsible party
Sponsor
First posted
Oct 31, 2017
Start date
Oct 25, 2017
Primary completion
Jun 11, 2018
Completion
Nov 14, 2018
Results posted
Sep 10, 2021
Last update
Apr 21, 2022

Study contacts

Klaus Theobald, MD, PhD
study director · Eirion Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion